¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¼¼°è µðÁöÅÐ ÈíÀԱ⠽ÃÀåÀº 2024³â 183¾ï 3,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç 2031³â¿¡´Â 643¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2031³â±îÁö ¿¬Æò±Õ 19.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í ¹üÀ§ |
º¸°í¼ »ó¼¼³»¿ë |
±âÁس⵵ |
2023³â |
2024³â ½ÃÀå ±Ô¸ð |
183¾ï 3,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2019-2023³â |
¿¹Ãø ±â°£ |
2024-2031³â |
¿¹Ãø±â°£(2024-2031³â)ÀÇ CAGR |
19.60% |
2031³â °¡Ä¡ ¿¹Ãø |
643¾ï 3,000¸¸ ´Þ·¯ |
±×¸². 2024³â Áö¿ªº° µðÁöÅÐ ÈíÀԱ⠽ÃÀå Á¡À¯À²(%)

.
µðÁöÅÐ ÈíÀÔ±â´Â õ½ÄÀ̳ª COPD¿Í °°Àº È£Èí±â ÁúȯÀ» Ä¡·áÇϱâ À§ÇØ ¾à¹° Àü´Þ¿¡ »ç¿ëµÇ´Â ÈÞ´ë¿ë ÈÞ´ë¿ë ÀåÄ¡ÀÔ´Ï´Ù. ÀÌ ÀåÄ¡´Â ÈíÀÔ °ø±â¸¦ °¨ÁöÇϰí ÈíÀÔÀ» À§ÇØ °ø±â ¿¡¾î·ÎÁ¹ ÇüÅ·ΠÁ¤È®ÇÑ ¾çÀÇ ¾à¹°À» ¹æÃâÇÕ´Ï´Ù. µðÁöÅÐ ÈíÀÔ±â´Â ±âÁ¸ÀÇ °¡¾Ð½Ä Á¤·® ÈíÀԱ⳪ °ÇÁ¶ ºÐ¸» ÈíÀԱ⿡´Â ¾ø´Â ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. µðÁöÅÐ ÈíÀԱ⿡´Â ¼¾¼°¡ ÀåÂøµÇ¾î ÀÖ¾î ¾à¹° »ç¿ëÀ» ÀÚµ¿À¸·Î ÃßÀûÇÏ°í ºí·çÅõ½º¸¦ ÅëÇØ µ¥ÀÌÅ͸¦ ÷ºÎµÈ ¾ÛÀ¸·Î Àü¼ÛÇÒ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ÀÇ»çÀÇ ¿ø°Ý ¸ð´ÏÅ͸µÀÌ °¡´ÉÇÏ¿© º¹¾à ¼øÀÀµµ¸¦ º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬°áµÈ ±â´ÉÀ» ÅëÇØ ÈíÀÔ±â´Â ȯÀÚ¿¡°Ô Çǵå¹é ¹× ¾Ë¸²À» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. µðÁöÅÐ ÈíÀÔ±â´Â °³ÀÎÈµÈ Ä¡·á, ¾ö°ÝÇÑ ¼øÀÀµµ ¸ð´ÏÅ͸µ, µðÁöÅÐ °Ç° ¼Ö·ç¼Ç°úÀÇ ÅëÇÕÀ» ÅëÇØ È£Èí±â ȯÀÚÀÇ Ä¡·á °á°ú¸¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ :
¼¼°è µðÁöÅÐ ÈíÀԱ⠽ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ¾à¹° ¼øÀÀµµ¿¡ ´ëÇÑ °ü½É Áõ°¡, È£Èí±â Áúȯ °ü¸®¿¡ ´ëÇÑ Á¤ºÎÀÇ À¯¸®ÇÑ ³ë·Â, Ä¿³ØÆ¼µå µðÁöÅÐ °Ç° ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀå ¼ºÀåÀº ±âÁ¸ ÈíÀԱ⿡ ºñÇØ µðÁöÅÐ ÈíÀÔ±âÀÇ °³¹ß ¹× Á¦Á¶¿Í °ü·ÃµÈ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠ±¹°¡¿¡¼´Â µðÁöÅÐ Ä¡·á Àåºñ¿¡ ´ëÇÑ »óȯ Á¤Ã¥ÀÌ ºÎÁ·ÇÏ¿© º¸±ÞÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀü, ÀÎÅͳݰú ½º¸¶Æ®ÆùÀÇ º¸±Þ Áõ°¡, È£Èí±â Áúȯ ¿ÜÀÇ µðÁöÅÐ ÈíÀԱ⠻ç¿ë È®´ë´Â ½ÃÀå ±â¾÷µé¿¡°Ô Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀÔ´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
- ÀÌ º¸°í¼´Â ¼¼°è µðÁöÅÐ ÈíÀԱ⠽ÃÀåÀ» ½ÉÃþ ºÐ¼®Çϰí 2023³âÀ» ±âÁØ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2024-2031³â) µ¿¾È ½ÃÀå ±Ô¸ð(¹ÌÈ 10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
- ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
- ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
- ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú ¹× Àü·«°ú °°Àº ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è µðÁöÅÐ ÈíÀԱ⠽ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
- ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
- ¼¼°è µðÁöÅÐ ÈíÀԱ⠽ÃÀåÀº ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
- ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è µðÁöÅÐ ÈíÀԱ⠽ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
- º¸°í¼ ¼³¸í
- ÁÖ¿ä ¿ä¾à
- Coherent Opportunity Map(COM)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
- ¿µÇ⠺м®
- ½ÃÀå µ¿Çâ
- ÃÖ±Ù µ¿Çâ
- Àμö ¹× Á¦ÈÞ ½Ã³ª¸®¿À
- Á¦Ç° ¹ß¸Å/½ÂÀÎ
- ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ
- PEST ºÐ¼®
- PorterÀÇ Five Forces ºÐ¼®
Á¦4Àå ¼¼°èÀÇ µðÁöÅÐ ÈíÀԱ⠽ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ
- ÀüüÀûÀÎ ¿µÇâ
- Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
- ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ
Á¦5Àå ¼¼°èÀÇ µðÁöÅÐ ÈíÀԱ⠽ÃÀå, Á¦Ç°º°, 2019³â-2031³â
- Á¤·® ºÐ¹«½Ä ÈíÀÔ±â(MDI)
- µå¶óÀÌ ÆÄ¿ì´õ ÈíÀÔ±â(DPI)
- ±âŸ
Á¦6Àå ¼¼°èÀÇ µðÁöÅÐ ÈíÀԱ⠽ÃÀå, À¯Çüº°, 2019³â-2031³â
Á¦7Àå ¼¼°èÀÇ µðÁöÅÐ ÈíÀԱ⠽ÃÀå, ÀûÀÀÁõº°, 2019³â-2031³â
- õ½Ä
- ¸¸¼º Æó¼â¼º ÆóÁúȯ
- ±âŸ
Á¦8Àå ¼¼°èÀÇ µðÁöÅÐ ÈíÀԱ⠽ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2019³â-2031³â
Á¦9Àå ¼¼°èÀÇ µðÁöÅÐ ÈíÀԱ⠽ÃÀå, Áö¿ªº°, 2019³â-2031³â
- ºÏ¹Ì
- ¹Ì±¹
- ij³ª´Ù
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ¾Æ¸£ÇîÆ¼³ª
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- ASEAN
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- 秵- °ÉÇÁÇù·ÂȸÀÇ
- À̽º¶ó¿¤
- ±âŸ Áßµ¿
- ¾ÆÇÁ¸®Ä«
- ºÏ¾ÆÇÁ¸®Ä«
- Áß¾Ó¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
Á¦10Àå °æÀï ±¸µµ
- ±â¾÷ °³¿ä
- 3M
- AstraZeneca
- GLENMARK PHARMACEUTICALS LTD.
- Novartis AG
- Sensirion AG
- Propeller Health
- OPKO Health, Inc.
- Teva Pharmaceutical Industries Ltd.
- BEXIMCO Pharmaceuticals
- GSK plc.
- Mundhipharma International
- Honeywell International Inc.
- Veranex
- Cognita Labs
Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý
LSH 24.05.17
Global digital dose inhaler market is estimated to be valued at USD 18.33 Bn in 2024 and is expected to reach USD 64.33 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 19.6% from 2024 to 2031.
Report Coverage |
Report Details |
Base Year: |
2023 |
Market Size in 2024: |
US$ 18.33 Bn |
Historical Data for: |
2019 to 2023 |
Forecast Period: |
2024 To 2031 |
Forecast Period 2024 to 2031 CAGR: |
19.60% |
2031 Value Projection: |
US$ 64.33 Bn |
Figure. Digital Dose Inhaler Market Share (%), By Region 2024

Digital dose inhalers are portable handheld devices that are used for delivering medication to treat respiratory diseases like asthma and COPD. These devices detect inspiration and release an exact dose of medication in the air aerosolized form for inhalation. Digital dose inhalers offer several advantages over conventional pressurized metered dose inhalers and dry powder inhalers. These are equipped with sensors that can track medication use automatically and transmit the data via Bluetooth to a companion app. This enables remote monitoring by physicians and ensures medication adherence. The connected features also allow the inhalers to provide feedback and reminders to patients. Digital dose inhalers aim to improve treatment outcomes for respiratory patients through personalized therapies, strict adherence monitoring, and integration with digital health solutions.
Market Dynamics:
Global digital dose inhaler market growth is driven by growing prevalence of respiratory diseases globally, increasing focus on medication adherence, favorable government initiatives for respiratory disease management, and rising awareness about connected digital health solutions. However, the market growth can be hampered by high costs associated with developing and manufacturing digital inhalers as compared to conventional inhalers. Lack of reimbursement policies for digital therapeutic devices in some countries also hampers its adoption. Continual technological advancements, increasing internet and smartphone penetration, expanding applications of digital inhalers beyond respiratory diseases present significant growth opportunities for market players.
Key Features of the Study:
- This report provides in-depth analysis of the global digital dose inhaler market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global digital dose inhaler market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study includes 3M, AstraZeneca, GLENMARK PHARMACEUTICALS LTD., Novartis AG, Sensirion AG, Propeller Health, OPKO Health, Inc., Teva Pharmaceutical Industries Ltd., BEXIMCO Pharmaceuticals, GSK plc., Mundhipharma International, Honeywell International Inc., Veranex and Cognita Labs
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global digital dose inhaler market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global digital dose inhaler market
Detailed Segmentation-
- Product:
- Metered Dose Inhaler (MDI)
- Dry Powder Inhaler (DPI)
- Others
- Type:
- Indication:
- End User:
- Hospitals
- Homecare Settings
- Others
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- 3M
- AstraZeneca
- GLENMARK PHARMACEUTICALS LTD.
- Novartis AG
- Sensirion AG
- Propeller Health
- OPKO Health, Inc.
- Teva Pharmaceutical Industries Ltd.
- BEXIMCO Pharmaceuticals
- GSK plc.
- Mundhipharma International
- Honeywell International Inc.
- Veranex
- Cognita Labs
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Type
- Market Snapshot, By Indication
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Product Launches/Approvals
- Fundings and Investments
- PEST Analysis
- Porter's Analysis
4. Global Digital Dose Inhaler Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Digital Dose Inhaler Market, By Product, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Metered Dose Inhaler (MDI)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Dry Powder Inhaler (DPI)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Digital Dose Inhaler Market, By Type, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Branded
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Generic
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Digital Dose Inhaler Market, By Indication, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Asthma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- COPD
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Digital Dose Inhaler Market, By End User, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Homecare Settings
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
9. Global Digital Dose Inhaler Market, By Region, 2019 - 2031, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GLENMARK PHARMACEUTICALS LTD.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mundhipharma International
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Honeywell International Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact